<DOC>
	<DOCNO>NCT00288730</DOCNO>
	<brief_summary>The purpose study assess safety efficacy two dose intravenous NATRECORÂ® hBNP ( recombinant form natural human peptide normally secreted heart ) versus placebo treatment patient symptomatic , decompressed congestive heart failure ( CHF ) .</brief_summary>
	<brief_title>A Study Two Doses Intravenous NATRECOR hBNP ( Nesiritide ) Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing Rest</brief_title>
	<detailed_description>Human study report SJ Holmes et al , 1993 , AM Richards et al , 1993 M. Yoshimara et al , 1991 show administration externally produce hBNP produce vasodilation ; antagonism hormone system help regulate long term blood pressure blood volume body ; increase urine output contain large amount salt . These study suggest hBNP may potent agent treatment acute congestive heart failure ( CHF ) unique combination desirable effect flow blood throughout body ; hormone secrete nervous system ; support copious salt output renal system provide currently available therapy . Plasma hBNP level elevate CHF hBNP may one body 's natural compensatory mechanism augment cardiac function fail heart . NATRECOR® hBNP Scios ' proprietary form hBNP identical amino acid sequence naturally occur hormone . This randomized , double-blinded , placebo-controlled , multicenter study determine efficacy two distinct dos NATRECOR® hBNP patient symptomatic , decompensated congestive heart failure decrease pulmonary capillary wedge pressure , measure blind comparison placebo 6 hour treatment . Patients randomize receive either placebo one two dos ( 0.015 0.03 µg/kg/min ) NATRECOR® hBNP . The study hypothesis NATRECOR ® hBNP well tolerate effective agent short-term management hospitalize patient symptomatic , decompensated CHF . Patients randomize receive either placebo one two dos ( 0.015 0.03 µg/kg/min ) NATRECOR® hBNP . Doses administered one time , intravenous load bolus , follow continuous intravenous infusion 6 hour .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>History chronic congestive heart failure ( CHF ) symptomatic , decompensated CHF intravenous therapy deem appropriate hospitalize patient documentation pulmonary capillary wedge pressure ( PCWP ) &gt; = 18 mm Hg , Cl &lt; = 2.7 mL/min/m² systolic blood pressure &gt; = 90 mm Hg consistent baseline hemodynamic measurement . Had myocardial infarction within previous 48 hour unstable angina stroke within previous 3 month evidence significantly compromised central nervous system perfusion significant valvular stenosis hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsyproven active myocarditis , complex congenital heart disease receive ongoing treatment intravenous vasostrictive agent episode decompress CHF could discontinue appropriate washout period permit reassessment baseline hemodynamic clinical status prior initiate drug study clinical status unstable subject tolerate placement SwanGanz catheter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Renal Dysfunction</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Decompensation</keyword>
	<keyword>Dyspnea Paroxysmal</keyword>
</DOC>